Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404001 · ClinicalTrials.gov registry record · Phase 2
Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
A Phase 2 study of Hypercholesterolemia, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT00404001 is a Phase 2 study of Hypercholesterolemia that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 150 participants, below the 814-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT00404001, a Phase 2 study of Hypercholesterolemia, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to evaluate the safety of MD-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C) lowering effect and dose-response of MD-0727 in patients with primary hypercholesterolemia.
Conditions Studied
Interventions
- DRUG MD-0727
Study Locations (20)
California
- Microbia Investigational Site - Los Angeles
- Microbia Investigational Site - Walnut Creek
North Carolina
- Microbia Investigational Site - Statesville
- Microbia Investigational Site - Winston-Salem
Ohio
- Microbia Investigational Site - Cincinnati
- Microbia Investigational Site - Marion
Washington
- Microbia Investigational Site - Lakewood
- Microbia Investigational Site - Olympia
Alabama
- Microbia Investigational Site - Birmingham
Florida
- Microbia Investigational Site - New Port Richey
Illinois
- Microbia Investigational Site - Chicago
Indiana
- Microbia Investigational Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404001
The ClinicalTrials.gov registry entry for NCT00404001 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 814-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (82% lower). The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which MD-0727 is the first listed.
NCT00404001 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT00404001 about?
NCT00404001 is a clinical study titled "Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia". The primary objectives of this study are to evaluate the safety of MD-0727 in patients with primary hypercholesterolemia and to determine the low density lipoprotein cholesterol (LDL-C) lowering effect and dose-response of MD-0727 in patients with primary hypercholesterolemia.
What is the current status of trial NCT00404001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2006-11. Estimated completion is 2007-07.
What conditions does trial NCT00404001 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT00404001?
The interventions under investigation include: MD-0727 (DRUG).
Who is sponsoring clinical trial NCT00404001?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00404001 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
COMPLETED · Phase 2
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
COMPLETED · Phase 2
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.